» Articles » PMID: 6352628

Studies on Absorption, Distribution, Metabolism and Excretion of Ceftazidime in Japan

Overview
Date 1983 Jul 1
PMID 6352628
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Ceftazidime achieved mean serum levels of 54.6 and 119.7 mg/l at 5 min and 0.9 and 1.9 mg/l at 8 h after an intravenous bolus injection of 0.5 and 1 g in healthy male adult volunteers, showing a dose-related increase in serum levels. Serum half-lives were in the range from 1.6 to 1.7 h. About 90% of the given dose was excreted in the urine during the first 24 h. Following a 1-h intravenous drip infusion of 1 and 2 g, ceftazidime attained peak serum levels of 69.5 and 150.8 mg/l at the end of the infusion. Eighty-three and 90%, respectively, of the given doses were excreted in the urine during 24 h after the administration of 1 and 2 g of ceftazidime. When serum levels were compared after intravenous bolus injections of 1 g of ceftazidime and 1 g of cefoperazone in a crossover fashion, results were very similar for both compounds, but the 24-h urinary recovery rate was about three times higher with ceftazidime than with cefoperazone. An intravenous injection of 1 g ceftazidime resulted in peak biliary levels about 4 h after administration, longer than that of ceftizoxime compared in a crossover fashion, and subsequently fairly high levels were maintained for a longer time. Ceftazidime penetrated gall bladder tissues at concentrations sufficient to inhibit most of the pathogenic bacteria. In the urine collected from healthy volunteers 1 h after an intravenous injection of 1 g ceftazidime, no active metabolite was detected.

Citing Articles

Application of Physiologically Based Pharmacokinetic Model to Delineate the Impact of Aging and Renal Impairment on Ceftazidime Clearance.

Abduljalil K, Gardner I, Jamei M Antibiotics (Basel). 2024; 13(9).

PMID: 39335035 PMC: 11429240. DOI: 10.3390/antibiotics13090862.


Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.

Berkhout J, Visser L, van den Broek P, van de Klundert J, Mattie H Antimicrob Agents Chemother. 2003; 47(6):1862-6.

PMID: 12760859 PMC: 155817. DOI: 10.1128/AAC.47.6.1862-1866.2003.


The pharmacokinetics of ceftazidime in lactating and non-lactating cows.

Rule R, Quiroga G, Rubio M, Buschiazzo H, Buschiazzo P Vet Res Commun. 1996; 20(6):543-50.

PMID: 8950835 DOI: 10.1007/BF00396297.


Cephalosporin-probenecid drug interactions.

Brown G Clin Pharmacokinet. 1993; 24(4):289-300.

PMID: 8491057 DOI: 10.2165/00003088-199324040-00003.


Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions.

Lakings D, Friis J, Brown R, Allen H Antimicrob Agents Chemother. 1984; 26(6):802-6.

PMID: 6524897 PMC: 180027. DOI: 10.1128/AAC.26.6.802.